How many insider trades does FilingIQ track for FATE?

FilingIQ tracks 583 Form 4 insider transactions for FATE (FATE THERAPEUTICS INC), covering filings from Apr 13, 2015 onwards. 18 of those were filed in the last 90 days.

Are FATE insiders net buyers or net sellers?

Across the full Form 4 history for FATE, 14 transactions (2%) were open-market purchases and 360 (62%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does FATE insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is FATE in?

FATE THERAPEUTICS INC (FATE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $178.81M.

FATE insider trading

NasdaqGM Healthcare

FATE THERAPEUTICS INC — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

583

Last 90 days

Buys / sells

2% / 62%

Market cap

$178.81M

About FATE THERAPEUTICS INC

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Company website: www.fatetherapeutics.com

FATE insider activity at a glance

FilingIQ has scored 583 insider transactions for FATE since Apr 13, 2015. The most recent filing in our index is dated May 6, 2026.

Across the full history, 14 open-market purchases and 360 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on FATE insider trades is 53.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live FATE trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding FATE

JOHNSON & JOHNSON (JNJ)

$4.26M · 0.8% of AUM

Frequently asked

How many insider trades does FilingIQ track for FATE?: FilingIQ tracks 583 Form 4 insider transactions for FATE (FATE THERAPEUTICS INC), covering filings from Apr 13, 2015 onwards. 18 of those were filed in the last 90 days.
Are FATE insiders net buyers or net sellers?: Across the full Form 4 history for FATE, 14 transactions (2%) were open-market purchases and 360 (62%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does FATE insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is FATE in?: FATE THERAPEUTICS INC (FATE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $178.81M.

Methodology & sources

Every FATE insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.